Editorial: High Baseline ALT Level Confers Risk of Hepatic Adverse Events During Immune Checkpoint Inhibitors Treatment: A Call for Caution—Authors' Reply DOI Open Access
Yi‐Ping Hung, Yi‐Hsiang Huang

Alimentary Pharmacology & Therapeutics, Год журнала: 2025, Номер unknown

Опубликована: Янв. 7, 2025

We express our sincere gratitude to Dr. Ze-Hua Zhao and Yu-Chen Fan for a comprehensive assessment professional insight into research [1, 2]. Both ≥ grade 3 hepatitis flare irHepatitis are unpredictable during treatment with immune checkpoint inhibitors (ICIs). A practical model predict the risk of immune-related (irHepatitis) based on baseline alanine aminotransferase (ALT) level indeed an unmet need. Unfortunately, in multivariate analyses study, no other clinical factor than ALT could be identified build model. It reflects unpredictability liver events associated ICIs therapy. Cirrhosis is common patients hepatocellular carcinoma (HCC), but underlying cirrhosis may not necessarily higher odds abnormalities. In 88 190 (46.3%) HCC 177 1093 (16.6%) without had > 40 U/L. Of course, has abnormalities due tumour involvement. Among HCC, 124 (65.3%) cirrhosis, which 63 (50.8%) U/L, was significantly compared non-cirrhotic (25/66 = 37.9%, p 0.095), showing that abnormal still certain role predicting cases [3]. During data analysis, we tried different levels as cut-offs, performance improved further. Given differences characteristics pathogenesis between cancer types, sought investigate differential hepatic after ICI therapy these cancers. Our findings suggest serve predictive across all types development or irHepatitis. pointed out double-edged sword, will increase B virus (HBV) reactivation (HBVr) absence nucleos/tide analogues (NUCs) accelerate loss surface antigen (HBsAg) achieve functional cure HBV viral-suppressed according studies [2, 4]. fully agree comments. there potential HBVr under NUC prophylaxis prevent 3]. For whose suppressed by NUCs, effect T-cell restoration beneficial HBsAg loss. believe addressing issues can better elucidate findings. thank their enlightening insights. Yi-Ping Hung: writing – original draft, software, visualization. Yi-Hsiang Huang: review editing, curation, validation, supervision, funding acquisition, resources. staff members Clinical Research Core Laboratory at Taipei Veterans General Hospital technical assistance. The authors declare conflicts interest. This article linked Hung et al papers. To view articles, visit https://doi.org/10.1111/apt.18403 https://doi.org/10.1111/apt.18422. support this study available request from corresponding author. publicly privacy ethical restrictions.

Язык: Английский

Editorial: High Baseline ALT Level Confers Risk of Hepatic Adverse Events During Immune Checkpoint Inhibitors Treatment: A Call for Caution—Authors' Reply DOI Open Access
Yi‐Ping Hung, Yi‐Hsiang Huang

Alimentary Pharmacology & Therapeutics, Год журнала: 2025, Номер unknown

Опубликована: Янв. 7, 2025

We express our sincere gratitude to Dr. Ze-Hua Zhao and Yu-Chen Fan for a comprehensive assessment professional insight into research [1, 2]. Both ≥ grade 3 hepatitis flare irHepatitis are unpredictable during treatment with immune checkpoint inhibitors (ICIs). A practical model predict the risk of immune-related (irHepatitis) based on baseline alanine aminotransferase (ALT) level indeed an unmet need. Unfortunately, in multivariate analyses study, no other clinical factor than ALT could be identified build model. It reflects unpredictability liver events associated ICIs therapy. Cirrhosis is common patients hepatocellular carcinoma (HCC), but underlying cirrhosis may not necessarily higher odds abnormalities. In 88 190 (46.3%) HCC 177 1093 (16.6%) without had > 40 U/L. Of course, has abnormalities due tumour involvement. Among HCC, 124 (65.3%) cirrhosis, which 63 (50.8%) U/L, was significantly compared non-cirrhotic (25/66 = 37.9%, p 0.095), showing that abnormal still certain role predicting cases [3]. During data analysis, we tried different levels as cut-offs, performance improved further. Given differences characteristics pathogenesis between cancer types, sought investigate differential hepatic after ICI therapy these cancers. Our findings suggest serve predictive across all types development or irHepatitis. pointed out double-edged sword, will increase B virus (HBV) reactivation (HBVr) absence nucleos/tide analogues (NUCs) accelerate loss surface antigen (HBsAg) achieve functional cure HBV viral-suppressed according studies [2, 4]. fully agree comments. there potential HBVr under NUC prophylaxis prevent 3]. For whose suppressed by NUCs, effect T-cell restoration beneficial HBsAg loss. believe addressing issues can better elucidate findings. thank their enlightening insights. Yi-Ping Hung: writing – original draft, software, visualization. Yi-Hsiang Huang: review editing, curation, validation, supervision, funding acquisition, resources. staff members Clinical Research Core Laboratory at Taipei Veterans General Hospital technical assistance. The authors declare conflicts interest. This article linked Hung et al papers. To view articles, visit https://doi.org/10.1111/apt.18403 https://doi.org/10.1111/apt.18422. support this study available request from corresponding author. publicly privacy ethical restrictions.

Язык: Английский

Процитировано

0